参考文献/References:
[1] 吴良银, 李文丽, 刘俊．基于GEO 数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J]. 现代检验医学杂志, 2021, 36(6): 106-110. WU Liangyin, LI Wenli, LIU Jun. Screening and bioinformatics analysis of potential biomarkers for virus-associated hepatocellular carcinoma based on GEO data[J]. Journal of Modern Laboratory Medicine,2021, 36(6): 106-110.
[2] JESENKO T, BREZAR S K, CEMAZAR M, et al. Targeting non-coding RNAs for the development of novel hepatocellular carcinoma therapeutic approaches[J]. Pharmaceutics, 2023, 15(4): 1249.
[3] HASHEMI M, MIRZAEI S, ZANDIEH M A, et al. Long non-coding RNAs (lncRNAs) in hepatocellular carcinoma progression: biological functions and new therapeutic targets[J]. Progress in Biophysics and Molecular Biology, 2023, 177: 207-228.
[4] HUANG Manling, LONG Jianting, YAO Zhijia, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma[J].Cancer Research, 2023, 83(1): 89-102.
[5] 魏英, 王小林. 肝癌组织中lncRNA-PRR34-AS1 的表达特性及其对肝癌细胞增殖、迁移的影响和潜在分子机制[J]. 现代检验医学杂志, 2021, 36(6): 41-46, 100. WEI Ying, WANG Xiaolin. Expression characteristics of lncRNA-PRR34-AS1 in liver cancer tissues and its effects on proliferation and migration of liver cancer cells and potential molecular mechanism[J]. Journal of Modern Laboratory Medicine, 2021, 36(6): 41-46, 100.
[6] YUAN Donghong, CHEN Yu, LI Xiaobing, et al. Long non-coding RNAs: potential biomarkers and targets for hepatocellular carcinoma therapy and diagnosis[J].International Journal of Biological Sciences, 2021,17(1): 220-235.
[7] CHEN B W, ZHOU Yue, WEI Tao, et al. LncRNAPOIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p[J].Journal of Cellular Biochemistry, 2021, 122(1): 130-142.
[8] XU Yongzi, LIU Yanhui, LI Zhenrong, et al. Long noncoding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR-675[J].Oncology Reports, 2020, 44(1): 165-173.
[9] ZHANG Pengfei, WANG Fei, WU Jing, et al. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma[J]. Journal of Cellular Physiology, 2019, 234(3): 2788-2794.
[10] LI Wei, HE Yufeng, CHEN Wei, et al. Knockdown of LINC00467 contributed to Axitinib sensitivity in hepatocellular carcinoma through miR-509-3p/PDGFRA axis[J]. Gene Therapy, 2021, 28(10-11): 634-645.
[11] SHI Yang, YANG Xiaohua, XUE Xiaofeng, et al. HANR enhances autophagy-associated sorafenib resistance through miR-29b/ATG9A axis in hepatocellular carcinoma [J]. Onco Targets and Therapy, 2020, 13: 2127-2137.
[12] XIE Chen, ZHANG Lizhen, CHEN Zhanli, et al. A hMTR4-PDIA3P1-miR-125/124-TRAF6 regulatory axis and its function in NF kappa B signaling and chemoresistance[J]. Hepatology, 2020, 71(5): 1660-1677.
[13] CAO Yongxian, ZHANG Feng, WANG Haotian, et al. LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis[J]. Molecular and Cellular Biochemistry,2021, 476(1): 279-292.
[14] DONG Jinyun, QIN Zuodong, ZHANG Weidong,et al. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update[J]. Drug Resistance Updates, 2020, 49: 100681.
[15] HUANG Hai, CHEN Jie, DING Chengming, et al. LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363[J]. Journal of Cellular and Molecular Medicine, 2018, 22(6): 3238-3245.
[16] YUAN Peng, CAO Weibin, ZANG Quanling, et al. The HIF-2α-MALAT1-miR-216b axis regulates multidrug resistance of hepatocellular carcinoma cells via modulating autophagy[J]. Biochemical and Biophysical Research Communications, 2016, 478(3): 1067-1073.
[17] KONG Jiehong, QIU Yajing, LI Yuan, et al. TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis[J]. Biopharmaceutics and Drug Disposition, 2019, 40(2): 70-80.
[18] SUN Yu, SHEN Yongming, LIANG Xiurui, et al. MicroRNAs as biomarkers and therapeutic targets for nonalcoholic fatty liver disease: a narrative review[J].Clinical Therapeutics, 2023, 45(3): 234-247.
[19] 陈偲, 李忠辉, 王颖．miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志, 2022, 37(4): 23-29. CHEN Si, LI Zhonghui, WANG Ying. Study on the mechanism of miR-198 inhibiting the proliferation and migration of hepatoma cells by regulating EMT process by targeting ZEB2[J]. Journal of Modern Laboratory Medicine, 2022, 37(4): 23-29.
[20] 刘国振, 陈秀余, 张修欢. 血清 miR-122-5p,miR486-5p,AFP 及 AFP-L3 水平联合检测对原发性肝癌的诊断价值[J]. 现代检验医学杂志, 2022, 37(1): 82-87. LIU Guozhen, CHEN Xiuyu, ZHANG Xiuhuan. Value of combined detection of serum miR-122-5p, miR-486-5p, AFP and AFP-L3 levels in the diagnosis of primary liver cancer[J]. Journal of Modern Laboratory Medicine, 2022, 37(1): 82-87.
[21] LIAO Zhaofu, CHEN Yilin, DUAN Chuncui, et al. Cardiac telocytes inhibit cardiac microvascular endothelial cell apoptosis through exosomal miRNA-21-5p-targeted cdip1 silencing to improve angiogenesis following myocardial infarction[J]. Theranostics, 2021,11(1): 268-291.
[22] JI Lin, LIN Zhongjie, WAN Zhe, et al. MiR-486-3p mediates hepatocellular carcinoma sorafenib resistance by targeting FGFR4 and EGFR[J]. Cell Death & Disease, 2020, 11(4): 250.
[23] FU Xiao, LIU Mengjie, QU Shengyang, et al. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway[J]. Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 52.
[24] LI Dong, WANG Tao, SUN Feifan, et al. Micro RNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma[J]. Cancer Gene Therapy, 2021, 28(1/2): 126-140.
[25] LIU Jiatao, FAN Lulu, YU Hanqing, et al. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages[J].Hepatology, 2019, 70(1): 241-258.
[26] WISCHHUSEN J C, CHOWDHURY S M, LEE T, et al. Ultrasound-mediated delivery of miRNA-122 and anti-miRNA-21 therapeutically immunomodulates murine hepatocellular carcinoma in vivo[J]. Journal of Controlled Release, 2020, 321: 272-284.
[27] XIE Haitao, ZHANG Qiugui, ZHOU Hui, et al. MicroRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells[J].Cytotechnology, 2018, 70(2): 513-521.
[28] HUANG Jinlong, FU Yipeng, GAN Wei, et al. Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-RORα-Wnt/β-Catenin axis[J]. Cancer Letters, 2020, 476: 140-151.
[29] XU Yunxiuxiu, LAI Yu, CAO Linhui, et al. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelialmesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10[J]. RNA Biology, 2021,18(10): 1408-1423.
[30] YANG Jianyu, CUI Ronghua, LIU Yingke. MicroRNA-212-3p inhibits paclitaxel resistance through regulating epithelial-mesenchymal transition,migration and invasion by targeting ZEB2 in human hepatocellular carcinoma[J]. Oncology Letters, 2020,20(4): 23.
[31] RAGHEB M A, SOLIMAN M H, ELZAYAT E M,et al. MicroRNA-520c-3p modulates doxorubicinchemosensitivity in HepG2 cells[J]. Anticancer Agents in Medicinal Chemistry, 2021, 21(2): 237-245.
[32] LIU Guodong, YIN Lei, OUYANG Xiwu, et al. M2 macrophages promote HCC cells invasion and migration via miR-149-5p/MMP9 signaling[J]. Journal of Cancer, 2020, 11(5): 1277-1287.
[33] IGNATOVA V V, KAISER S, HO J S Y, et al. METTL6 is a tRNA m3C methyltransferase that regulates pluripotency and tumor cell growth[J].Science Advances, 2020, 6(35): eaaz4551.
[34] KUANG Muyu, ZHENG Difan, TAO Xiaoting, et al. tRNA-based prognostic score in predicting survival outcomes of lung adenocarcinomas[J]. International Journal of Cancer, 2019, 145(7): 1982-1990.
[35] LI Jiao, ZHU Lei, CHENG Jian, et al. Transfer RNAderived small RNA: a rising star in oncology[J].Seminars in Cancer Biology, 2021, 75: 29-37.
[36] ZHANG Ruyi, NOORDAM L, OU Xumin, et al. The biological process of lysine-tRNA charging is therapeutically targetable in liver cancer[J]. Liver International, 2021, 41(1): 206-219.
[37] ZHU Lei, LI Jiao, GONG Youling, et al. Exosomal tRNA-derived small RNA as a promising biomarker for cancer diagnosis[J]. Molecular Cancer, 2019, 18(1): 74.
[38] NISHIMOTO A, MIURA N, OSHIMURA M. Clinical significance of telomerase activity in precancerous lesion of the liver (adenomatous hyperplasia)[J]. Nihon Rinsho, 1998, 56(5): 1244-7.
[39] ZHOU Yongqiang, HU Jinjing, LIU Lu, et al. GlytRF enhances LCSC-like properties and promotes HCC cells migration by targeting NDFIP2[J]. Cancer Cell International, 2021, 21(1): 502.
[40] LIU Dekai, WU Chengdong, WANG Jingjie, et al. Transfer RNA-derived fragment 5’tRF-Gly promotes the development of hepatocellular carcinoma by direct targeting of carcinoembryonic antigen-related cell adhesion molecule 1[J]. Cancer Science, 2022, 113(10):3476-3488.
[41] WU Chengdong, LIU Dekai, ZHANG Lufei, et al. 5’-tiRNA-Gln inhibits hepatocellular carcinoma progression by repressing translation through the interaction with eukaryotic initiation factor 4A-I[J].Frontiers of Medicine, 2023, 17(3): 476-492.
[42] SONG Beibei, WU Siyu, YE Liyun, et al. Circular RNA 0000157 depletion protects human bronchial epithelioid cells from cigarette smoke extract-induced human bronchial epithelioid cell injury through the microRNA-149-5p/bromodomain containing 4 pathway[J]. Human & Experimental Toxicology, 2023,42: 9603271231167581.
[43] HUA Xiang, LI Jiazheng, SHANG Mingwei, et al. Pathogenesis of psoriasis via miR-149-5p/AKT1axis by long noncoding RNA BLACAT1[J]. Skin Research and Technology, 2023, 29(5): e13339.
相似文献/References:
[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12
and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(02):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1
Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(02):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG
in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[4]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence
and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(02):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[5]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(02):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[6]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related
to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(02):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[7]吴良银a,李文丽b,刘 俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(02):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[8]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(02):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[9]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(02):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[10]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(02):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]